Back to search results

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

Israel
RecruitingPHASE3

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Conditions

Primary Immunoglobulin A Nephropathy (IgAN)

Locations
  • Childrens Hospital Colorado, Aurora, Colorado, United States
  • Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
  • Prim Childrens Hosp Inv Pharm, Salt Lake City, Utah, United States
  • Novartis Investigative Site, Brisbane, Queensland, Australia
  • Novartis Investigative Site, Nedlands, Western Australia, Australia
  • Novartis Investigative Site, Hangzhou, Zhejiang, China
  • Novartis Investigative Site, Beijing, China
  • Novartis Investigative Site, Hong Kong, Hong Kong
  • Novartis Investigative Site, Beersheba, Israel
  • Novartis Investigative Site, Haifa, Israel
  • Novartis Investigative Site, Jerusalem, Israel
  • Novartis Investigative Site, Petah Tikva, Israel
  • Novartis Investigative Site, Kurume, Fukuoka, Japan
  • Novartis Investigative Site, Ohtsu, Shiga, Japan
  • Novartis Investigative Site, Fuchū, Tokyo, Japan
View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)